A Phase 2 interventional study of Interferon beta-1a and Placebo in Alzheimer's Disease, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Italy. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-02-13.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Alzheimer Disease with a site in Italy — 54 open to participants now, 73 under way, 19 of them phase 3. Alzheimer Disease · Italy.
Among the 206 studies in Alzheimer Disease with a site in Italy, this one is the 153rd largest by enrollment of the 170 interventional ones that give a count, is the only one that started in 2004, is one of 36 in phase 2, and was the 22nd registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →54 of the 206 studies in Alzheimer Disease with a site in Italy are open now. Recruiting first, the newest first:
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Sites in Italy
Ages 18+
University of Siena · Sites in Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 55–80 · Healthy volunteers
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Italy, Australia, Austria and 14 more countries
Ages 18+
Casa di Cura Dott. Pederzoli · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 47 · Phase 3 75 · Phase 4 2
First in 2003; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 328 across the 170 interventional studies, 273 across the 36 observational. Of the 124 that completed or were terminated, 64 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 206 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 1 study filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
14 of the studies in Alzheimer Disease with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT06402838Hoffmann-La RocheA Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) | 2026-11-19 |
| NCT06179680IRCCS Policlinico S. DonatoWhite Matter Hyperintensities in Amnestic Mild Cognitive Impairment or Alzheimer's Disease | 2026-12 |
Add all 14 to your calendar (.ics) → With an account.
Among the 206 studies in Alzheimer Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a 52-week, multicentric, phase II, pilot study conducted in 40 subjects with early-onset Alzheimer's disease (AD) to evaluate safety, tolerability and clinical efficacy of subcutaneous (sc) interferon (IFN) beta-1a [Rebif® 22 microgram (mcg), three times per week (tiw)] in the treatment of AD by comparing the neuropsychological performance changes into placebo and treatment arms from screening/baseline to 52 week.
Alzheimer's disease is characterized by progressive cognitive impairment resulting from neuronal loss. The primary pathological feature of the disease is the extracellular deposition of fibrillary amyloid and its compaction into senile plaques. The senile plaque is the focus of a complex cellular reaction involving the activation of both microglia and astrocytes adjacent to the amyloid plaque. In fact, microglias are the most abundant and prominent cellular components associated with these plaques. Plaque-associated microglia exhibits a reactive or activated phenotype. Through the acquisition of a reactive phenotype, microglia responds to various stimuli, as is evident by the increased expression of numerous cell-surface molecules, including major histocompatibility complex (MHC) class-II antigens and complement receptors.
Traditionally, multiple sclerosis (MS) has been considered a "demyelinating" disease. Recent immunocytochemical studies suggest that MS may be more than a demyelinating disorder, and that even in early stages of the disease, MS pathological scenario envisages axonal damage. Interferons, the modern therapeutic strategies for the treatment of MS, are cytokines - proteins which lead to a network of signals within different cells. In the immune system, IFNs act at different levels. For example, IFNs increase the expression of MHC class II antigens and, thereby, facilitate the antigen-presenting process and the activation of lymphocytes. T-lymphocytes are important targets of IFN immunomodulation. In MS, it is believed that IFN beta suppresses the production of proinflammatory cytokines such as IFN-γ and TNF-α, and increases the production of immunosuppressive cytokines such as interleukin-4 (IL-4) and IL-10. Since the activation of microglia and astrocytes is common to both AD and MS, IFN beta could have therapeutic applications in the treatment of AD. Furthermore, recent studies have also found that through astrocyte production, IFNs promote the activation of nerve-growth factor.
OBJECTIVES
In this study, subjects were randomized into two groups: the first group (treatment arm, n=20) received Rebif® 22 mcg tiw; the second group (placebo arm, n=20) received placebo. The treatment period was for 28 weeks and subjects were followed up to Week 52. Efficacy was determined by comparing neuropsychological performance changes into placebo and treatment arms from screening/baseline to Week 52.
On Day 1 of the study treatment period, subjects received injection training and were administered the first dose of Rebif under the supervision of the clinical personnel by subcutaneous injection tiw at approximately the same time each day preferably in the late afternoon or evening. All subjects received 28 weeks of therapy and after 24 weeks from the therapy conclusion, a termination visit was conducted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjets in this arm received interferon beta-1a (Rebif® 22 mcg tiw)
Drug: Interferon beta-1a
Subjects in this arm received placebo
Drug: Placebo
Interferon (IFN) beta-1a \[Rebif® 22 microgram (mcg), three times per week (tiw)\] administered subcutaneously (sc)
Also known as: Rebif®
The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way
Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog) Score
ADAS: global rating scale created to evaluate both cognitive and functional aspects linked with disease progression. ADAS-Cog: subscale of ADAS which consists in a series of short tests aimed to evaluate possible cognitive impairment due to disease progression. It includes 11 items, testing word-finding difficulty, following commands, naming: objects and fingers, orientation, word recognition, recall of test instructions, constructions, ideational praxis, spoken language ability, comprehension of spoken language and word recall. Scores range from 0 (no impairment) to 70 (serious deficit).
Time frame: Baseline and Week 52
Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog) Score
ADAS: global rating scale created to evaluate both cognitive and functional aspects linked with disease progression. ADAS-Cog: subscale of ADAS which consists in a series of short tests aimed to evaluate possible cognitive impairment due to disease progression. It includes 11 items, testing word-finding difficulty, following commands, naming: objects and fingers, orientation, word recognition, recall of test instructions, constructions, ideational praxis, spoken language ability, comprehension of spoken language and word recall. Scores range from 0 (no impairment) to 70 (serious deficit).
Time frame: Week 12 and 28
Mini Mental Status Examination (MMSE) Score
MMSE is a tool for screening cognitive decline associated with dementia. It is a brief examination intended to evaluate an adult participant's level of cognitive functioning. The test is performed in following areas: orientation in time and place, learning and immediate recall, mental control and concentration, short-term recall, naming ability, language expression, verbal comprehension, writing comprehension, writing ability and visual-spatial coordination. Scores range between 0 (maximum cognitive deficit) and 30 (no cognitive deficit).
Time frame: Baseline, Week 12, 28 and 52
Alzheimer's Disease Assessment Scale, Non-cognitive Subscale (ADAS-NonCog) Score
ADAS-NonCog is a subscale of ADAS aimed to evaluate the non-cognitive features such as mood state and behavioral changes. It takes about 10 minutes to be performed and includes 10 items: testing tearful, depressed mood, concentration/distractibility, uncooperative to testing, delusions, hallucinations, pacing, motor activity increase, tremors and appetite change. Scores range between 0 (excellent performance) and 35 (worst performance).
Time frame: Baseline, Week 12, 28 and 52
Instrumental Activities of Daily Living (IADL) Score
IADL is used to evaluate participants with early-stage disease, both to assess level of disease and to determine participant's ability of self-care. IADL scale measures functional impact of emotional, cognitive, and physical impairments. It provides information about participants' compromising rate and care he might need. It includes 8 items: testing ability to use telephone, shopping, food preparation, housekeeping, laundry, mode of transportation, responsibility for own medication and ability to handle finances. Scores range between 0 (impairment) and 8 (full independence).
Time frame: Baseline, Week 28 and 52
Physical Self-Maintenance Scale (PSMS) Score
PSMS designed as a disability measure for use in planning and evaluating treatment in elderly participants living in community or in institutions, is Guttman scale containing 6 items of self-care. The scale is based on theory that human behavior can be ordered in a hierarchy of complexity, within each category, a further hierarchy of complexity runs from basic to complex activities. It includes 6 items, testing the following areas: toilet use, eating, dressing, physical appearance, deambulation and bath. Scores range between 0 (excellent performance) and 30 (worst performance).
Time frame: Baseline, Week 28 and 52
Clinician's Interview Based Impression of Change (CIBIC-PLUS) Score
CIBIC-PLUS: structured instrument based on comprehensive evaluation of 3 domains: participant cognition, behavior and functioning, including assessment of daily living activities. It includes 15 items and represents assessment of skilled clinician using validated scales based on the observation at interviews conducted separately with participant and caregiver familiar with behavior of participant. According to comparison between baseline and follow-up assessments, scores can range between 1 (markedly improved) and 7 (markedly worsened), with 4 indicating no change observed between two visits.
Time frame: Week 28 and 52
Geriatric Depression Scale (GDS) Score
The GDS consists of 30 'yes' or 'no' items aimed to assess depression. One point is assigned to each answer and the cumulative score is rated on a scoring grid. Scores are grouped as follows: 0-9 'normal', 10-19 'mildly depressed', and 20-30 'severely depressed'.
Time frame: Baseline, Week 28 and 52
Global Deterioration Scale Score
Global deterioration scale includes seven different diagnostic stages ranging between "no cognitive deterioration" and "very serious cognitive deterioration". It investigates the cognitive impairment. Scores range between 1 (no cognitive deterioration) and 7 (very severe cognitive decline).
Time frame: Baseline, Week 28 and 52
| Milestone | Rebif 22 Mcg | Placebo |
|---|---|---|
| Started | 23 | 19 |
| Completed | 19 | 15 |
| Not completed | 4 | 4 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 |
ADAS: global rating scale created to evaluate both cognitive and functional aspects linked with disease progression. ADAS-Cog: subscale of ADAS which consists in a series of short tests aimed to evaluate possible cognitive impairment due to disease progression. It includes 11 items, testing word-finding difficulty, following commands, naming: objects and fingers, orientation, word recognition, recall of test instructions, constructions, ideational praxis, spoken language ability, comprehension of spoken language and word recall. Scores range from 0 (no impairment) to 70 (serious deficit).
| units on a scale | Rebif 22 Mcg | Placebo |
|---|---|---|
| Baseline | 18.63 ± 7.86 | 19.81 ± 6.15 |
| Week 52 | 20.66 ± 9.55 | 20.33 ± 10.05 |
ADAS: global rating scale created to evaluate both cognitive and functional aspects linked with disease progression. ADAS-Cog: subscale of ADAS which consists in a series of short tests aimed to evaluate possible cognitive impairment due to disease progression. It includes 11 items, testing word-finding difficulty, following commands, naming: objects and fingers, orientation, word recognition, recall of test instructions, constructions, ideational praxis, spoken language ability, comprehension of spoken language and word recall. Scores range from 0 (no impairment) to 70 (serious deficit).
| units on a scale | Rebif 22 Mcg | Placebo |
|---|---|---|
| Week 12 | 16.74 ± 6.94 | 17.97 ± 6.28 |
| Week 28 | 18.49 ± 8.72 | 17.55 ± 7.02 |
MMSE is a tool for screening cognitive decline associated with dementia. It is a brief examination intended to evaluate an adult participant's level of cognitive functioning. The test is performed in following areas: orientation in time and place, learning and immediate recall, mental control and concentration, short-term recall, naming ability, language expression, verbal comprehension, writing comprehension, writing ability and visual-spatial coordination. Scores range between 0 (maximum cognitive deficit) and 30 (no cognitive deficit).
| units on a scale | Rebif 22 Mcg | Placebo |
|---|---|---|
| Baseline | 23.46 ± 2.14 | 22.93 ± 1.79 |
| Week 12 | 24.50 ± 3.22 | 24.66 ± 3.14 |
| Week 28 | 24.25 ± 3.37 | 23.66 ± 4.92 |
| Week 52 | 22.43 ± 5.33 | 21.98 ± 5.32 |
ADAS-NonCog is a subscale of ADAS aimed to evaluate the non-cognitive features such as mood state and behavioral changes. It takes about 10 minutes to be performed and includes 10 items: testing tearful, depressed mood, concentration/distractibility, uncooperative to testing, delusions, hallucinations, pacing, motor activity increase, tremors and appetite change. Scores range between 0 (excellent performance) and 35 (worst performance).
| units on a scale | Rebif 22 Mcg | Placebo |
|---|---|---|
| Baseline | 4.37 ± 4.13 | 6.07 ± 5.01 |
| Week 12 | 3.53 ± 3.24 | 4.73 ± 4.27 |
| Week 28 | 4.63 ± 4.36 | 5.20 ± 3.43 |
| Week 52 | 5.47 ± 5.17 | 7.20 ± 6.97 |
IADL is used to evaluate participants with early-stage disease, both to assess level of disease and to determine participant's ability of self-care. IADL scale measures functional impact of emotional, cognitive, and physical impairments. It provides information about participants' compromising rate and care he might need. It includes 8 items: testing ability to use telephone, shopping, food preparation, housekeeping, laundry, mode of transportation, responsibility for own medication and ability to handle finances. Scores range between 0 (impairment) and 8 (full independence).
| units on a scale | Rebif 22 Mcg | Placebo |
|---|---|---|
| Baseline | 6.11 ± 1.45 | 6.20 ± 1.57 |
| Week 28 | 5.84 ± 1.17 | 5.60 ± 1.68 |
| Week 52 | 4.89 ± 1.85 | 5.67 ± 1.63 |
PSMS designed as a disability measure for use in planning and evaluating treatment in elderly participants living in community or in institutions, is Guttman scale containing 6 items of self-care. The scale is based on theory that human behavior can be ordered in a hierarchy of complexity, within each category, a further hierarchy of complexity runs from basic to complex activities. It includes 6 items, testing the following areas: toilet use, eating, dressing, physical appearance, deambulation and bath. Scores range between 0 (excellent performance) and 30 (worst performance).
| units on a scale | Rebif 22 Mcg | Placebo |
|---|---|---|
| Baseline | 6.42 ± 1.02 | 6.40 ± 0.91 |
| Week 28 | 6.74 ± 1.37 | 7.00 ± 2.65 |
| Week 52 | 7.79 ± 3.34 | 6.87 ± 1.68 |
CIBIC-PLUS: structured instrument based on comprehensive evaluation of 3 domains: participant cognition, behavior and functioning, including assessment of daily living activities. It includes 15 items and represents assessment of skilled clinician using validated scales based on the observation at interviews conducted separately with participant and caregiver familiar with behavior of participant. According to comparison between baseline and follow-up assessments, scores can range between 1 (markedly improved) and 7 (markedly worsened), with 4 indicating no change observed between two visits.
| participants | Rebif 22 Mcg | Placebo |
|---|---|---|
| Week 28: CIBIC-PLUS Score 1 | 1 | 0 |
| Week 28: CIBIC-PLUS Score 2 | 0 | 2 |
| Week 28: CIBIC-PLUS Score 3 | 7 | 6 |
| Week 28: CIBIC-PLUS Score 4 | 8 | 5 |
| Week 28: CIBIC-PLUS Score 5 | 3 | 0 |
| Week 28: CIBIC-PLUS Score 6 | 0 | 2 |
| Week 28: CIBIC-PLUS Score 7 | 0 | 0 |
| Week 52: CIBIC-PLUS Score 1 | 0 | 0 |
| Week 52: CIBIC-PLUS Score 2 | 0 | 2 |
| Week 52: CIBIC-PLUS Score 3 | 6 | 2 |
| Week 52: CIBIC-PLUS Score 4 | 7 | 4 |
| Week 52: CIBIC-PLUS Score 5 | 1 | 4 |
| Week 52: CIBIC-PLUS Score 6 | 4 | 3 |
| Week 52: CIBIC-PLUS Score 7 | 1 | 0 |
The GDS consists of 30 'yes' or 'no' items aimed to assess depression. One point is assigned to each answer and the cumulative score is rated on a scoring grid. Scores are grouped as follows: 0-9 'normal', 10-19 'mildly depressed', and 20-30 'severely depressed'.
| units on a scale | Rebif 22 Mcg | Placebo |
|---|---|---|
| Baseline | 10.11 ± 6.13 | 10.67 ± 6.53 |
| Week 28 | 9.68 ± 5.74 | 9.07 ± 4.32 |
| Week 52 | 10.79 ± 5.93 | 7.50 ± 5.56 |
Global deterioration scale includes seven different diagnostic stages ranging between "no cognitive deterioration" and "very serious cognitive deterioration". It investigates the cognitive impairment. Scores range between 1 (no cognitive deterioration) and 7 (very severe cognitive decline).
| units on a scale | Rebif 22 Mcg | Placebo |
|---|---|---|
| Baseline | 3.00 ± 0.47 | 2.87 ± 0.74 |
| Week 28 | 3.05 ± 0.78 | 3.00 ± 0.93 |
| Week 52 | 3.26 ± 0.81 | 3.20 ± 1.08 |
Collected over Baseline to Week 52. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rebif 22 Mcg | — | 0/23 (0%) | 5/23 (21.7%) |
| Placebo | — | 0/19 (0%) | 5/19 (26.3%) |
| Event | Rebif 22 Mcg | Placebo |
|---|---|---|
| High CholesterolInvestigations | 3/23 | 0/19 |
| Articular PainMusculoskeletal and connective tissue disorders | 0/23 | 2/19 |
| High pseudocholinesteraseInvestigations | 2/23 | 1/19 |
| High level of aspartate aminotransferase (AST) - alanine transaminase (ALT)Investigations | 0/23 | 1/19 |
| High thyroid stimulating hormoneInvestigations | 0/23 | 1/19 |
| Low blood pressureVascular disorders | 0/23 | 1/19 |
| Right ear buzzingEar and labyrinth disorders | 0/23 | 1/19 |
| Flu-like syndromeGeneral disorders | 0/23 | 1/19 |
| FeverGeneral disorders | 1/23 | 0/19 |
| High level of alanine transaminase (ALT) and aspartate aminotransferase (AST)Investigations | 1/23 | 0/19 |
| Age, Continuous(years) | Rebif 22 Mcg | Placebo | Total |
|---|---|---|---|
| Mean | 63.00 ± 9.08 | 64.58 ± 6.41 | 63.71 ± 7.87 |
| Sex: Female, Male(Participants) | Rebif 22 Mcg | Placebo | Total |
|---|---|---|---|
| Female | 15 | 11 | 26 |
| Male | 8 | 8 | 16 |
The record gives a start of Nov 2004, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interferon beta-1a
Merck KGaA, Darmstadt, Germany →